Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Brugia malayi | Calcitonin receptor-like protein seb-1 | 0.1562 | 1 | 1 |
Loa Loa (eye worm) | RNA recognition domain-containing protein domain-containing protein | 0.0526 | 0.2737 | 0.2671 |
Echinococcus multilocularis | diuretic hormone 44 receptor GPRdih2 | 0.0494 | 0.2517 | 0.9168 |
Loa Loa (eye worm) | hypothetical protein | 0.0494 | 0.2517 | 0.2448 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.0209 | 0.052 | 1 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.0209 | 0.052 | 1 |
Toxoplasma gondii | LsmAD domain-containing protein | 0.0209 | 0.052 | 1 |
Brugia malayi | RNA binding protein | 0.0526 | 0.2737 | 0.2737 |
Schistosoma mansoni | tar DNA-binding protein | 0.0526 | 0.2737 | 0.4106 |
Brugia malayi | TAR-binding protein | 0.0526 | 0.2737 | 0.2737 |
Brugia malayi | isocitrate dehydrogenase | 0.0148 | 0.009 | 0.009 |
Schistosoma mansoni | hypothetical protein | 0.0494 | 0.2517 | 0.3764 |
Loa Loa (eye worm) | RNA binding protein | 0.0526 | 0.2737 | 0.2671 |
Schistosoma mansoni | hypothetical protein | 0.0494 | 0.2517 | 0.3764 |
Echinococcus granulosus | tar DNA binding protein | 0.0526 | 0.2737 | 1 |
Echinococcus granulosus | diuretic hormone 44 receptor GPRdih2 | 0.0494 | 0.2517 | 0.9168 |
Loa Loa (eye worm) | hypothetical protein | 0.0156 | 0.0143 | 0.0054 |
Brugia malayi | Latrophilin receptor protein 2 | 0.0494 | 0.2517 | 0.2517 |
Onchocerca volvulus | 0.0156 | 0.0143 | 0.5 | |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.0209 | 0.052 | 1 |
Brugia malayi | Isocitrate dehydrogenase | 0.0148 | 0.009 | 0.009 |
Echinococcus granulosus | GPCR family 2 | 0.0494 | 0.2517 | 0.9168 |
Echinococcus multilocularis | cadherin EGF LAG seven pass G type receptor | 0.0494 | 0.2517 | 0.9168 |
Schistosoma mansoni | tar DNA-binding protein | 0.0526 | 0.2737 | 0.4106 |
Schistosoma mansoni | hypothetical protein | 0.0494 | 0.2517 | 0.3764 |
Echinococcus multilocularis | GPCR, family 2 | 0.0494 | 0.2517 | 0.9168 |
Loa Loa (eye worm) | MH2 domain-containing protein | 0.0888 | 0.5274 | 0.5231 |
Brugia malayi | latrophilin 2 splice variant baaae | 0.1068 | 0.6536 | 0.6536 |
Leishmania major | hypothetical protein, conserved | 0.0209 | 0.052 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.1068 | 0.6536 | 0.6505 |
Brugia malayi | MH2 domain containing protein | 0.0888 | 0.5274 | 0.5274 |
Loa Loa (eye worm) | transcription factor SMAD2 | 0.0888 | 0.5274 | 0.5231 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.0209 | 0.052 | 1 |
Loa Loa (eye worm) | pigment dispersing factor receptor c | 0.1562 | 1 | 1 |
Schistosoma mansoni | hypothetical protein | 0.1068 | 0.6536 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0209 | 0.052 | 0.0434 |
Trypanosoma brucei | PAB1-binding protein , putative | 0.0209 | 0.052 | 1 |
Brugia malayi | RNA recognition motif domain containing protein | 0.0526 | 0.2737 | 0.2737 |
Mycobacterium tuberculosis | Probable isocitrate dehydrogenase [NADP] Icd1 (oxalosuccinate decarboxylase) (IDH) (NADP+-specific ICDH) (IDP) | 0.0148 | 0.009 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.1562 | 1 | 1 |
Brugia malayi | calcium-independent alpha-latrotoxin receptor 2, putative | 0.0494 | 0.2517 | 0.2517 |
Loa Loa (eye worm) | TAR-binding protein | 0.0526 | 0.2737 | 0.2671 |
Schistosoma mansoni | hypothetical protein | 0.0494 | 0.2517 | 0.3764 |
Plasmodium vivax | ataxin-2 like protein, putative | 0.0209 | 0.052 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0526 | 0.2737 | 0.4106 |
Brugia malayi | hypothetical protein | 0.0209 | 0.052 | 0.052 |
Brugia malayi | hypothetical protein | 0.0156 | 0.0143 | 0.0143 |
Loa Loa (eye worm) | latrophilin receptor protein 2 | 0.0494 | 0.2517 | 0.2448 |
Schistosoma mansoni | tar DNA-binding protein | 0.0526 | 0.2737 | 0.4106 |
Echinococcus multilocularis | tar DNA binding protein | 0.0526 | 0.2737 | 1 |
Echinococcus granulosus | cadherin EGF LAG seven pass G type receptor | 0.0494 | 0.2517 | 0.9168 |
Schistosoma mansoni | tar DNA-binding protein | 0.0526 | 0.2737 | 0.4106 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 23.2809 uM | PUBCHEM_BIOASSAY: Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID2660, AID2666, AID2667, AID2668, AID2681, AID504465] | ChEMBL. | No reference |
Potency (functional) | = 39.8107 um | PUBCHEM_BIOASSAY: qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent). (Class of assay: confirmatory) [Related pubchem assays: 2158 (Confirmation qHTS Assay for Inhibitors of Cruzain), 2249 (Probe Development Summary of Promiscuous Inhibitors (Artifacts) of Cruzain), 2161 (qHTS Assay for Inhibitors of Papain: Counterscreen for Cruzain Assay), 1478 (qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent))] | ChEMBL. | No reference |
Potency (binding) | = 50.1187 um | PUBCHEM_BIOASSAY: qHTS Assay for Identification of Novel General Anesthetics. In this assay, a GABAergic mimetic model system, apoferritin and a profluorescent 1-aminoanthracene ligand (1-AMA), was used to construct a competitive binding assay for identification of novel general anesthetics (Class of assay: confirmatory) [Related pubchem assays: 2385 (Probe Development Summary for Identification of Novel General Anesthetics), 2323 (Validation apoferritin assay run on SigmaAldrich LOPAC1280 collection)] | ChEMBL. | No reference |
Potency (functional) | = 89.1251 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of DNA Polymerase Beta. (Class of assay: confirmatory) | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.